Phase II Study of PEGPH20 and Pembrolizumab (MK-3475) for Patients With Previously Treated Hyaluronan High (HA-High) Metastatic Pancreatic Ductal Adenocarcinoma
Phase of Trial: Phase II
Latest Information Update: 09 May 2019
Price : $35 *
At a glance
- Drugs Hyaluronidase (Primary) ; Pembrolizumab (Primary)
- Indications Adenocarcinoma; Pancreatic cancer
- Focus Therapeutic Use
- 03 May 2019 Planned End Date changed from 1 Dec 2020 to 1 Jan 2021.
- 03 May 2019 Planned primary completion date changed from 1 Sep 2020 to 1 Oct 2020.
- 03 May 2019 Status changed from not yet recruiting to recruiting.